The Study Of Treating Gastroesophageal Reflux Disease With Surface Gastrointestinal Pacemaker Union Pantoprazole And The Effects On Gastrointestinal Hormone

Objective: To discuss the effects of Surface Gastrointestinal Pacemaker UnionDomperidone on the improvement of clinical efficacy for patients with GastroesophagealReflux Disease,and the effections of the gastrointestinal hormones.Methods: Considered the patients with Gastroesophageal Reflux Disease who fit oninclusion criteria and exclusion criteria,63cases were selected randomly, as observedobject. These patients were randomly divided into two groups:31patients in group A werereceived the treatment of pantoprazole enteric-coated capsules (40mg/Bid,2weeks) anddomperidone (10mg/Tid,2weeks);32Patients in group B were received treatments ofpantoprazole enteric-coated capsules (40mg/Bid,2weeks) union surface of gastrointestinalpacing (30min/Bid,2weeks).Each patients were recorded their symptom score, EGG, esophageal manometry,motilin, gastrin, cholecystokinin before and after treatment. Recorded the time of the firstrecurrence of symptoms for the patients with complete remission of symptoms after2weeks of treatment. Using SPSS statistical analysis these change of above outcomemeasures recorded before and after treatment.Results：1.The symptoms for the patients of group B are improved significantly thangroup A after1week treatment, the difference between two groups was statisticallysignificant(P <0.05), but was no significant difference after2weeks of treatment(P>0.05);2.In changes of LESP, there is no much diffence of the patients from group A and Bbefore treatment(P>0.05), after2weeks treatment, both patients from group A and B, theLESP elevated, but group B is significantly increased than group A, the difference wasstatistically significant (P <0.05);3.In changes of gastric electrogram bradycardia，postprandial/fasting power ratio, there is no much diffence between the patients of group A and B before treatment(P>0.05),but the patients of group B are improved significantly than group A after treatment, thedifference was statistically significant (P <0.05);4.In the gastrointestinal hormones, the two groups of patients has no difference beforetreatment(P>0.05),but patients in group B are significantly higher than group A in motilinand gastrin levels after treatment, the difference was statistically significance (P <0.05),cholecystokinin showed no significant difference both before and after treatment(P>0.05).5.In adverse reactions, patients of group B which union the treatment of surfacegastrointestinal pacing,appeared1case(3.13%) of partial burns of abdominal skin,excessively exhausting3cases (9.38%). While group A which patients taking domperidone,appeared diarrhea were2cases (6.45%), excessively exhausting were3cases (9.68%).6.In the first recurrence time, the patients of group B was significantly longer thangroup A, and the difference was statistically significant(P <0.05).Conclusions：1. Surface gastrointestinal pacemaker union pantoprazole cansignificantly increased the gastric electrogram bradycardia, postprandial/fasting powerratio, concentration of motilin and gastrin for patients with GERD, and promoted gastricmotility effectively;2. The treatment of surface gastrointestinal pacemaker union pantoprazole have theadvantages of fast onset, safe and hard to relapse in GERD...